First-Episode Schizophrenia

CNS Spectrums

Volumn 15, Issue S6, 2010, Pages 4-7

  Robinson, Delbert ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; CASE REPORT; COGNITION; FEMALE; HUMAN; PSYCHOLOGY; REVIEW; SCHIZOPHRENIA; SOCIAL SUPPORT; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; COGNITION; FEMALE; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL SUPPORT; TREATMENT OUTCOME;

EID: 79952113968     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900027681     Document Type: Article

References (32)

1. Emsley, RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull. 1999; 25(4):721–729.
2. Lieberman, JA, Phillips, M, Gu, H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003; 28(5):995–1003.
3. Lieberman, JA, Tollefson, G, Tohen, M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003; 160(8):1396–1404.
4. Schooler, N, Rabinowitz, J, Davidson, M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005; 162(5):947–953.
5. Robinson, DG, Woerner, MG, Napolitano, B, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry. 2006; 163(12):2096–2102.
6. McEvoy, JP, Lieberman, JA, Stroup, TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006; 163(4):600–610.
7. Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9):789–796.
8. McEvoy, JP, Lieberman, JA, Perkins, DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007; 164(7):1050–1060.
9. Kahn, RS, Fleischhacker, WW, Boter, H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008; 371(9618):1085–1097.
10. Harvey, PD, Rabinowitz, J, Eerdekens, M, Davidson, M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005; 162(10):1888–1895.
11. Keefe, RS, Seidman, LJ, Christensen, BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004; 161(6):985–995.
12. Keefe, RS, Sweeney, JA, Gu, H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007; 164(7):1061–1071.
13. Davidson, M, Galderisi, S, Weiser, M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009; 166(6):675–682.
14. Goldberg, TE, Goldman, RS, Burdick, KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007; 64(10):1115–1122.
15. Robinson, D, Woerner, MG, Alvir, JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999; 56(3):241–247.
16. Kane, JM, Rifkin, A, Quitkin, F, Nayak, D, Ramos-Lorenzi, J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry. 1982; 39(1):70–73.
17. Crow, TJ, MacMillan, JF, Johnson, AL, Johnstone, EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986; 148: 120–127.
18. McCreadie, RG, Wiles, D, Grant, S, et al. The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand. 1989; 80(6):597–602.
19. Hogarty, GE, Ulrich, RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res. 1998; 32(3–4):243–250.
20. Green, AI, Lieberman, JA, Hamer, RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006; 86(1–3):234–243.
21. Novak-Grubic, V, Tavcar, R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur Psychiatry. 2002; 17(3):148–154.
22. Coldham, EL, Addington, J, Addington, D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002; 106(4):286–290.
23. Robinson, DG, Woerner, MG, Alvir, JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002; 57(2–3):209–219.
24. Mutsatsa, SH, Joyce, EM, Hutton, SB, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 2003; 108(6):439–446.
25. Kamali, M, Kelly, BD, Clarke, M, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry. 2006; 21(1):29–33.
26. Perkins, DO, Johnson, JL, Hamer, RM, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006; 83(1):53–63.
27. Verdoux, H, Lengronne, J, Liraud, F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000; 102(3):203–210.
28. Mojtabai, R, Lavelle, J, Gibson, PJ, et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv. 2002; 53(3):337–339.
29. Liberman RP, KA, Ventura, J, Gutkind, D. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002; 14(4):256–272.
30. Robinson, DG, Woerner, MG, McMeniman, M, Mendelowitz, A, Bilder, RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004; 161(3):473–479.
31. Craig, TK, Garety, P, Power, P, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ. 2004; 329(7474):1067.
32. Jeppesen, P, Petersen, L, Thorup, A, et al. Integrated treatment of first-episode psychosis: effect of treatment on family burden: OPUS trial. Br J Psychiatry Suppl. 2005; 48: s85–90.